Thermo Fisher’s New Platform Boosts Biologics Development

Thermo Fisher Scientific, a leader in scientific services, has announced the launch of an innovative cell line development platform designed to expedite the development of biologics. The Gibco CHOvantage GS Cell Line Development Kit offers a high-output, streamlined approach for biologics developers, promising shorter timelines to clinical trials while maintaining scalability and regulatory compliance.

In response to the expanding global pipeline of protein therapeutics, including complex biologics and biosimilars used in treating diseases like cancer and autoimmune disorders, Thermo Fisher’s new platform addresses the increasing demand for faster, cost-effective development methods. The introduction of the CHOvantage GS Cell Line Development Kit promises to improve efficiency, allowing for the generation of high-performing CHO cell lines that can achieve protein yields of ≥7 g/L. By enabling the establishment of stable pools in just four weeks and supporting the selection of stable clones within 14 weeks, the platform supports a seamless transition from early development to commercial manufacturing.

In collaboration with BioFactura, a key pre-launch testing partner, Thermo Fisher demonstrates how the CHOvantage platform aligns with the industry’s need for reliable and scalable technologies. By simplifying tech transfer and enhancing process consistency, this new platform is poised to significantly impact the biologics sector, helping developers meet regulatory demands while speeding up time-to-market for critical therapies.